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Xionghui Zhou and Juan Liu*Abstract
Background: Although there are a lot of researches focusing on cancer prognosis or prediction of cancer
metastases, it is still a big challenge to predict the risks of cancer metastasizing to a specific organ such as bone.
In fact, little work has been published for such a purpose nowadays.
Methods: In this work, we propose a Dysregulated Pathway Based prediction Model (DPBM) built on a merged data
set with 855 samples. First, we use bootstrapping strategy to select bone metastasis related genes. Based on the
selected genes, we then detect out the dysregulated pathways involved in the process of bone metastasis via
enrichment analysis. And then we use the discriminative genes in each dysregulated pathway, called as dysregulated
genes, to construct a sub-model to forecast the risk of bone metastasis. Finally we combine all sub-models as an
ensemble model (DPBM) to predict the risk of bone metastasis.
Results: We have validated DPBM on the training, test and independent sets separately, and the results show that
DPBM can significantly distinguish the bone metastases risks of patients (with p-values of 3.82E-10, 0.00007 and 0.0003
on three sets respectively). Moreover, the dysregulated genes are generally with higher topological coefficients
(degree and betweenness centrality) in the PPI network, which means that they may play critical roles in the biological
functions. Further functional analysis of these genes demonstrates that the immune system seems to play an important
role in bone-specific metastasis of breast cancer.
Conclusions: Each of the dysregulated pathways that are enriched with bone metastasis related genes may uncover
one critical aspect of influencing the bone metastasis of breast cancer, thus the ensemble strategy can help to describe
the comprehensive view of bone metastasis mechanism. Therefore, the constructed DPBM is robust and able to
significantly distinguish the bone metastases risks of patients in both test set and independent set. Moreover, the
dysregulated genes in the dysregulated pathways tend to play critical roles in the biological process of bone
metastasis of breast cancer.
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Metastasis is the main cause of death in breast cancer
[1,2], and bone is the organ suffering from metastasis
most frequently [3]. Breast cancer patients with bone
metastases may suffer marked decreased mobility, patho-
logic fractures, neurological damage and other symptoms,
and the patients with high risks of bone metastases should
take agents tailored treatments [4,5]. Thus for cancer
therapy, it is essential to identify the prognostic factors* Correspondence: liujuan@whu.edu.cn
School of Computer, Wuhan University, Wuhan, P.R. China
© 2014 Zhou and Liu; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.which can help to identify the patients with high risks of
bone metastasis [4-6].
Because the ability of tumour cells metastasizing to a
specific organ is an inherent genetic property [7,8], it is
possible to predict bone metastasis of breast cancer by
using gene expression profiles [8]. However, up to now
only several researches have attempted to identify bone
metastasis related genes from gene expression data
[3,9-11], and only one in which [3] has made use of the
identified genes as signature to construct classification
model for predicting bone metastasis risk of breastl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ered very limited number of samples when selecting
gene signatures and did not perform strict independent
tests on any larger data set. As breast cancer is a heteroge-
neous disease, the characters associated with metastases
may vary widely across different patients [1]. Insufficient
patient samples would not cover all aspects of the metas-
tases, thus gene signatures selected from small number of
samples may not be credible enough. In fact, it has been
found out that the gene signatures identified using one
data set may perform badly on another data set [12-14].
In recent years, several methods have been used to de-
rive gene sets that are related to specific biological func-
tions, such as protein-protein interaction network [15],
pathway [16], GO Term [17], and so on. For example,
the gene set statistics method [17] infers the activity of
one gene set by counting all expression levels of genes in
the set, and then uses the activity to build the classifier
to predict the metastasis risk of breast cancer. Extracting
gene sets rather than selecting single genes can provide
more stable signatures, thus can construct classifiers
with higher performances [18]. However, most of the
existing methods consider all genes in the same set
equally without noticing that some genes are less im-
portant than others. In fact in a pathway or other kind
of gene set, only a part of genes would be dysregulated
during the metastasis process of cancer. Although Lee
et al. just considered a subset of the genes to infer the
activity of each pathway, and used all activities to con-
struct a model to classify cancer patients [18], there are
still two drawbacks. Firstly, this method uses the inferred
activities instead of the gene expression levels to construct
the classifier, resulting in the loss of some important infor-
mation for classification. Secondly, some pathways not
involved in the disease process may be considered im-
properly, leading that some noises could be imported into
the prediction model.
In this work, we present a new prediction model, Dys-
regulated Pathway Based prediction Model (DPBM), to
predict the risk of bone metastasis of breast cancer
(Figure 1). To get enough samples, we integrate four
breast cancer sets together to obtain 855 breast cancer
samples, from which we select genes that are signifi-
cantly correlated with bone metastasis of breast cancer
by using bootstrapping strategy. The selected genes are
also called as candidate genes. After that, we identify
KEGG pathways that are enriched by the candidate genes
as abnormal pathways in the bone metastasis process. We
call these pathways as dysregulated pathways and the
candidate genes involved in the dysregulated pathways
as dysregulated genes. Since different pathways are in-
volved in different aspects of the bone metastasis process,
the genes related to them can correspondently be divided
into different functional groups. Therefore, we can use thedysregulated genes in each pathway to construct one sub-
model, and then integrate all sub-models into an ensemble
model (DPBM) to predict the bone metastases risks of
breast cancer patients by majority voting strategy. We
evaluate DPBM both on test set and independent set in
terms of prediction accuracy and robustness. We also in-
vestigate the topological characteristics of the dysregulated
genes in protein-protein interaction network and their
functional annotations, trying to uncover the biological
mechanisms that play important roles in bone metastasis
of breast cancer.
Methods
Data sets and pre-processing
We have downloaded gene expression profiles of breast
cancer patients along with the clinical information from
UNC microarray database [8]. The downloaded data con-
sists of four microarray data sets: GSE2034 [19], GSE2603
[20], GSE12276 [21] and NKI295 [22], and has been
processed and normalized by the original paper [8].
Details of these data sets are shown in Table 1. In our
work, GSE2034 was used as an independent test set. As
for the other three data sets, we randomly selected 2/3
samples as the training set and the remainder samples
as the test set. As a result, we got a training set consist-
ing of 380 samples (113 are bone metastases and 267
are free of bone metastases) and a test set containing
189 samples (56 are bone metastases and 133 are free of
bone metastases). In these data sets, if the first metastasis
organ of a patient is bone, then the status is set as bone
metastasis, otherwise it is set as free of bone metastasis
(including cases of non-bone metastases and non
metastases).
We have also downloaded the human protein-protein
interactions from the HIPPI (Human Integrated Protein-
Protein Interaction rEference) [23], and the pathways
from the Molecular Signatures Database (MSigDB) [24].
Selecting candidate genes by bootstrapping
As is known to all, t-test is a popular method used to se-
lect discriminative genes, thus it could be used in our
work. However, t-test method requires that every sample
must be attached with a class label. While in our work,
for the reason that the clinical information of some pa-
tients is censored, not every sample can be assigned as
either low-risk or high-risk of bone metastasis according
to the widely used criterion that patients who are bone-
metastasized within a threshold of years belong to high-
risk group, and patients who are free of bone metastases
and survive longer than the threshold belong to low-risk
group, which results that some valuable samples not
satisfying the criterion have to be removed from the
training set if t-test method is used. Different with t-test
method, however, the Cox proportional hazards regression
Figure 1 The framework of DPBM prediction model.
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more proper for our work to select the bone metastasis
related genes.
In this work, we used a simple bootstrapping strategy
to select candidate genes of which expression levels
were significantly correlated with the bone metastasis
risk. Concretely, we first randomly selected 3/4 of all
the 380 samples from the training set; and then forTable 1 Breast cancer data sets
Data set Bone metastasis samples Metastasis samples Samples
GSE2034 69 95 286
GSE2603 14 24 82
GSE12276 102 173 192
NKI295 53 84 295
GSE2034 was used as an independent set. The other three data sets were
combined into one merged set, from which we randomly selected 2/3
samples into the training set and the other 1/3 samples into the test set.each gene, we applied Cox proportional hazards re-
gression to calculate the coefficient between the gene
expression level and the bone metastasis risk across
the chosen samples. The above procedure was repeated
400 times, and the genes with Cox p-values less than
0.05 in more than 80% of all runs were regarded as the
candidate genes. For every selected gene, its averaged
Cox coefficient and Cox p-value over all the 400 runs
were set to be its final corresponding values for further
calculations.Identifying the dysregulated pathways
The candidate genes are those significantly corre-
lated with bone metastasis risk. If the candidates are
enriched in a pathway (that is, the overlap of the
candidate genes and the genes in the pathway is sig-
nificant), then we call this pathway as a dysregulated
pathway. In this work, we applied the widely used
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test the significance of the overlap:












Where x stands for the size of intersection set; K rep-
resents the number of the candidate genes; N stands for
the number of the genes in the pathway; and M repre-
sents the number of all genes in our calculation (the uni-
versal gene set). For a pathway, if the p-value is less than
0.05, then it is considered as the dysregulated one; and
the genes belonging to the intersection set are called as
dysregulated genes.
Constructing the DPBM
With the hypothesis that one dysregulated pathway may
describe only one aspect of the bone metastasis mechan-
ism, while all dysregulated pathways can provide a com-
prehensive view of the bone metastasis, we adopted the
ensemble strategy [14] to construct DPBM to predict the
bone metastases risks of breast cancer patients. We chose
the dysregulated genes in each dysregulated pathway as
features to construct a sub-model to distinguish the bone
metastases risks of the patients, and all the sub-models
were integrated as DPBM by majority voting strategy.
To construct each sub-model, we used a simple strat-
egy, similar to the Gene expression Grade Index (GGI)
[25], to calculate the bone metastasis risk for every






Where xi (xj) represents the expression level of the
dysregulated gene i (j) which has a positive (negative)
Cox coefficient with metastasis risk. The higher the Risk-
Score is, the greater the risk of bone metastasis. We
applied 10-fold cross validation test to set the proper
threshold value of RiskScore. In each run, the n-th smal-
lest riskScore value (n is the number of training patients
free of bone metastases) in the training samples was set
as the cut-off to determine the class labels of the test
samples, based on which, the performance (log rank test)
can be obtained. The final threshold value was set as the
one with the best performance in ten runs. Any patient
with RiskScore value greater than this threshold is consid-
ered as high-risk of bone metastasis by this sub-model,
otherwise it is considered as low-risk of bone metastasis.
For a patient, if more than half sub-models vote for
“high-risk of bone metastasis”, it will be finally predicted as
“high-risk of bone metastasis” by DPBM, and vice versa. In
order to assess the performance of DPBM, we used the log
rank test to evaluate the significance of the risk differencesbetween the patients in two groups. Kaplan Meier
curves and the log rank test were performed using a tool
(http://www.mathworks.com/matlabcentral/fileexchange/
22317-logrank).
Topologically investigating dysregulated genes in PPI
network
Protein-protein interaction network has been success-
fully applied to select signature genes [26]. For example,
Hase et al. illustrated that the signature genes tended to
have bigger degrees in the network [27]; and Yao et al.
reported that the signature genes were usually with higher
betweenness centralities in the network [28]. Thus we
investigated two network topological coefficients (Degree
and Betweenness Centrality) of the selected dysregulated
genes by comparing with candidate genes (dysregulated
genes excluded) and all genes in the PPI network (dys-
regulated genes excluded). The differences of the topo-
logical coefficients between the dysregulated genes and
other two kinds of genes were tested by the Mann–
Whitney-Wilcoxon non-parametric test for two unpaired
groups. And the topology analysis of PPI network was
performed by the Network Analyzer plug-in for Cytos-
cape [29].
Investigating dysregulated genes by functional analysis
DAVID [30] was applied to extract the GO Terms (Bio-
logical Processes) which were significantly enriched by
the dysregulated genes and the ones with p-values less
than 0.05 were set as enriched GO Terms. All enriched
GO Terms were clustered into several functional groups
by the functional annotation clustering method with the
default threshold of enrichment score [30].
Results
Dysregulated pathways and genes
By bootstrapping method, we selected out 267 candidate
genes (Additional file 1: Table S1), from which we got 35
dysregulated genes involved in eight dysregulated path-
ways (Table 2). In order to validate our strategy, we also
used t-test to select the discriminative genes between
the patients of the high-risk group and the low-risk
group (see Additional file 1: Supplementary Methods),
based on which, the dysregulated genes as well as dys-
regulated pathways can be gotten by using the similar
strategy to ours. As a result, most of the identified dys-
regulated pathways and genes based on the candidates
selected by bootstrapping method are significantly coin-
cident with those selected by t-test method (Additional
file 1: Figure S1). Moreover, most of the dysregulated
pathways and genes are shown to be related to bone
metastasis in literature.
Some cytokines have been reported to be related to
breast invasion and metastasis site [31], while cytokine
Table 2 The dysregulated pathways
KEGG pathway Enrichment p-value Gene ID Gene symbol Cox coefficient Cox p-value Stability
Cytokine Cytokine Receptor Interaction 0.029 355 FAS −0.42 0.0048 0.9925
1235 CCR6 −0.22 0.023 0.905
1439 CSF2RB −0.32 0.0046 0.9875
2322 FLT3 −0.28 0.015 0.93
3561 IL2RG −0.20 0.031 0.8125
3570 IL6R −0.37 0.027 0.85
3575 IL7R −0.23 0.0044 0.995
4982 TNFRSF11B −0.22 0.019 0.9125
6363 CCL19 −0.11 0.033 0.8025
6375 XCL1 −0.21 0.013 0.9575
7042 TGFB2 −0.24 0.016 0.9325
7422 VEGFA 0.15 0.031 0.83
Chemokine Signaling Pathway 0.041 112 ADCY6 0.34 0.032 0.8225
1235 CCR6 −0.22 0.023 0.905
3702 ITK −0.18 0.023 0.87
3717 JAK2 −0.48 0.0025 1
5579 PRKCB1 −0.39 0.021 0.8975
5613 PRKX −0.26 0.031 0.815
5829 PXN 0.34 0.021 0.8725
6363 CCL19 −0.11 0.033 0.8025
6375 XCL1 −0.21 0.013 0.9575
Cell Cycle 0.012 894 CCND2 −0.27 0.013 0.96
1021 CDK6 −0.48 0.010 0.955
1869 E2F1 0.32 0.0015 1
1870 E2F2 0.33 0.031 0.8375
7042 TGFB2 −0.24 0.016 0.9325
8243 SMC1A 0.75 0.0085 0.98
9700 ESPL1 0.25 0.010 0.97
10744 PTTG2 0.46 0.011 0.975
Natural Killer Cell Mediated Cytotoxicity 0.048 355 FAS −0.42 0.0048 0.9925
3002 GZMB −0.23 0.0067 0.985
3383 ICAM1 −0.32 0.022 0.8975
3821 KLRC1 −0.43 0.0073 0.97
3932 LCK −0.24 0.025 0.875
5579 PRKCB1 −0.39 0.021 0.8975
22914 KLRK1 −0.34 0.015 0.9325
T Cell Receptor Signaling Pathway 0.046 917 CD3G −0.43 0.00097 0.9975
3702 ITK −0.18 0.023 0.87
3932 LCK −0.24 0.025 0.875
5788 PTPRC −0.21 0.024 0.8675
10892 MALT1 −0.43 0.015 0.905
29851 ICOS −0.41 0.018 0.915
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Table 2 The dysregulated pathways (Continued)
Pancreatic Cancer 0.027 1021 CDK6 −0.48 0.010 0.955
1869 E2F1 0.32 0.0015 1
1870 E2F2 0.33 0.031 0.8375
7042 TGFB2 −0.24 0.016 0.9325
7422 VEGFA 0.15 0.031 0.83
Non Small Cell Lung Cancer 0.0095 1021 CDK6 −0.48 0.010 0.955
1869 E2F1 0.32 0.0015 1
1870 E2F2 0.33 0.031 0.8375
5579 PRKCB1 −0.39 0.021 0.8975
6256 RXRA 0.45 0.012 0.9525
Primary Immunodeficiency 0.0014 3561 IL2RG −0.20 0.031 0.8125
3575 IL7R −0.23 0.0044 0.995
3932 LCK −0.24 0.025 0.875
5788 PTPRC −0.21 0.024 0.8675
29851 ICOS −0.41 0.018 0.915
The first column contains the names of the pathways; the second column contains the enrichment p-value of the candidate genes to the pathways; the third col-
umn (Gene ID) and the forth column (Gene Symbol) contains all candidate genes in the pathways; the fifth column contains the average Cox coefficients of the
genes in the 400 runs; the fifth column contains the average p-values of the genes in the 400 runs and the last column contains the stability of the genes in the
400 runs (the ratios of the genes are significant across all the 400 runs). In the table, there are 35 unique genes (some genes may be present at more than
one pathways).
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in our work. What is more, the dysregulated genes IL2RG,
IL6R, IL7R and TGFB2 have been reported to be associ-
ated with metastasis site or prognosis [31], and CCR6 is
associated with both live metastasis in breast cancer [32]
and bone metastasis in human neuroblastoma [33].
Chemokines and their receptors have been shown to
play critical roles in determining the metastatic destin-
ation of tumour cells [34]. In our work, the chemokine
signalling pathway is also enriched with the candidate
genes. In the meanwhile, among the nine dysregulated
genes, Jak2 has been reported to be mediated by IL6 to
involve in bone metastasis [35]; CCR6 is associated with
bone metastasis [33]; PPKX regulates endothelial cell
migration and vascular-like structure formation [36];
XCL1 and CCL19 are associated with organ specific
metastasis [34,37].
Cell cycle pathway plays an important role in tumori-
genesis and cancer prognosis [38], and it has also been
found to be dysregulated in our work. Among its dysreg-
ulated genes, CCND2 is differentially expressed between
breast cancer patients with bone metastases and other
patients [11]; E2F1 can regulate DZ13 to induce a cyto-
toxic stress response in tumour cells metastasizing to
bone [39]; TGFB2 is related to the bone metastases
development [40].
It is interesting that non-small cell lung cancer and
pancreatic cancer pathways have also be found dysregu-
lated in bone metastasis. In fact, lung is the organ with
the second frequent metastasis for breast cancer [8], and
it has been reported that some breast cancer wouldmetastasize to pancreatic [41]. This phenomenon sug-
gests that either lung cancer or pancreatic cancer might
share some common mechanisms with bone metastasis
of breast cancer, for the dysregulated genes E2F1 [39]
and TGFB2 [40] in pancreatic cancer pathway have been
shown to be also involved in bone metastasis process;
while E2F2 gene, the family member of E2F1, has been
found to be the dysregulated gene in the non-small cell
lung pathway.
We have also found that three immune related path-
ways have been dysregulated in bone metastasis of
breast cancer: natural killer cell mediated cytotoxicity
pathway, T cell receptor signalling pathway and primary
immunodeficiency pathway. In fact, some immune re-
lated genes are essential in bone metastasis of breast
cancer [42-44], and their family members, such as FAS,
IL2RG and IL7R, have shown dysregulated in our work
and have been reported to be either metastasis related
or bone metastasis related [31,35,45].
Now that references [3,9-11] have published bone
metastasis related genes, we merged all the reported genes
and investigated the overlap with our dysregulated genes.
It is surprising that there are only four common
genes (Additional file 1: Figure S2) between two sets
of genes. We thus investigated the functions of published
genes and found that they are most enriched in ‘metabolic
process’ (data not shown), while our dysregulated genes
are mainly related to immune system. By literature investi-
gation, we further found that the immune cells can play
essential roles in bone metastasis or metastasis of cancer
[42,44], which illustrates that our dysregulated genes are
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tasis, compared to the reported genes.
Distinguishing bone metastasis risk by DPBM
From the training set we have extracted eight dysregu-
lated pathways for bone metastasis in breast cancer,
based on which, eight sub-models were constructed and
then integrated into DPBM for predicting the bone me-
tastases risks of patients. Therefore, we decided to evalu-
ate DPBM on the training set, test set and independent
set respectively.
Just as expected, DPBM performed well in the training
set. Among all the 380 patients, 308 have been classified
as low-risk of bone metastases, and 72 as high-risk of
bone metastases. The hazard ratio of the two groups was
3.25 (95% CI 2.21 – 4.78), with p-value of 3.82E-10
(Figure 2a).
Then we validated DPBM on the test set and found it
also performed very well. Among the 189 patients, 150
samples were predicted as low-risk and the others as
high-risk. Survival analysis showed that the hazard ratio
was 2.89 (95% CI 1.67 – 5.00), with p-value of 0.00007
(Figure 2b).
It is notable that both the training and test sets belong
to the same integrated data set, the test set is hardly in-
dependent with the training set even though it has not
taken part in the construction of DPBM. Therefore, it
would be bias to evaluate DPBM just with the test set or
even with the training set. Herein, we also used a com-
pletely independent set, GSE2034, to evaluate DPBM.
The result shows that DPBM consistently performed well
in the independent set. Among the 286 samples, 218 pa-
tients were predicted as low-risk group and the other 68
ones were assigned into the high-risk group. The hazard
ratio between the two groups was 2.35 (95% CI 1.44 –Figure 2 Kaplan-Merier curves of the risk groups for breast cancer pa
set. (b) Result in the test set. (c) Result in the independent set.3.83), and the p-value of log rank test was 0.0003
(Figure 2c).
We noticed that different types of samples in any of
the training, test and independent sets are imbalanced,
which would lead to the overestimation problem. In
order to address this issue, we also used random sam-
pling methodology to choose the same number of cases
from high-risk and low-risk groups and re-evaluated the
DPBM on each of three data sets. We repeated the
above process 1000 times, and the means of hazard ra-
tios for training test and independent sets were 3.31
(p-value of 2.49E-04), 3.15 (p-value of 0.0082) and 2.48
(p-value of 0.015) respectively (Additional file 1: Table S2).
The results further unveil the robustness of our model. In
the meanwhile, the stable performance of the DPBM also
indicates the reliability of the dysregulated genes identified
by our method.
Topological analysis of dysregulated genes in PPI network
The degrees and betweenness centralities of three groups
of genes (35 dysregulated genes, 232 candidate genes (the
dysregulated genes excluded), all genes (the dysregulated
genes excluded) in PPI network) are shown in Figure 3(a)
and Figure 3(b) respectively, where three gene groups are
correspondingly denoted as ‘Dysregulated genes’, ‘Candi-
date genes’ and ‘All genes’.
From Figure 3(a), it is clear that the dysregulated
genes tend to have bigger degrees than the other two
groups of genes, and the p-values of dysregulated vs
candidate genes, dysregulated vs all genes are 2.29E-04
and 4.86E-07 respectively. Moreover, Figure 3(b) demon-
strates that the betweenness centralities of the dysregu-
lated genes are usually bigger than the other two groups
of genes (with p-value = 1.17E-05 and p-value = 1.68E-08
separately).tients with bone metastasis-free survival. (a) Result in the training
Figure 3 Comparison of the topological parameters in the PPI network among the three groups (Dysregulated genes, Candidate genes
(except for the dysregulated genes) and All genes (except for the dysregulated genes) in the PPI network). (a) Comparison of the degrees.
(b) Comparison of the betweenness centralities.
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genes take up more important positions in the PPI net-
work than the other genes, and tend to be essential
genes for the bone metastasis.Difference between bone and non-bone metastasis
We noticed that there are also some samples metasta-
sized to other organs instead of bone in the data sets. By
using the same strategy as we have done for bone metas-
tasis, we have found nine dysregulated pathways and a
total of 67 dysregulated genes related to non-bone me-
tastases (metastases to other organs except for bone)
(Additional file 1: Table S3). Therefore, we investigated
the different functional groups to which these two kinds
of genes belong, with the purpose of uncovering the
biological mechanism of bone specific metastasis. By
function annotating and clustering, the 35 dysregulated
genes of bone metastasis were found to belong to 16
functional groups (Additional file 2: Table S4), and the
67 dysregulated genes of non-bone metastases were
found to belong to 15 functional clusters (Additional
file 3: Table S5).
By comparison, we found that these two kinds of genes
shared a lot of common functional clusters. For example,
cell differentiation related cluster, cell cycle related
cluster, cell migration cluster, apoptosis related cluster,
hormone stimulus related cluster, phosphate metabolic
process and phosphorylation related cluster. As is knownto all, cell differentiation, cell cycle, cell migration, and
cell apoptosis are all famous caner hallmark related GO
Terms that are related to cancer and cancer prognosis
[46-48], while hormones are related to the risk of breast
cancer and hormones-replacement therapy is a common
therapy for breast cancer patients [49]. In addition, phos-
phorylation of some proteins have been reported to be
related to breast cancer [50] and cancer prognosis [51].
The main difference between these two kinds of dys-
regulated genes was that dysregulated genes of bone
metastasis are also enriched in biological processes asso-
ciated with immune system, whereas dysregulated genes
of non-bone metastases were not. The difference sug-
gests that the immune system may be essential in the
bone specific metastasis of breast cancer.Comparing DPBM with other classification methods
In DPBM, we simply used a cut-off of the RiskScore in
each dysregulated pathways to make a prediction, instead
of training a complex classifier such as SVM (Support
Vector Machine). In order to evaluate this option, we
herein adopted two strategies to construct SVM classifers
and investigated their performances. By one strategy, we
used the RiskScore values of the eight dysregulated path-
ways as eight features to construct a SVM classifier. By
the other strategy, we used all the 35 dysregulated genes
as features to construct another SVM classifier to predict
the bone metastasis risk. To construct both SVM
Table 3 Comparing DPBM with other methods
Training data set Test data set Independent data set
AUC Accuracy AUC Accuracy AUC Accuracy
DPBM 0.76 0.64 0.60 0.60 0.61 0.66
SVM (RiskScore) 0.72 0.71 0.58 0.59 0.60 0.60
SVM (dysregulated genes) 0.75 0.75 0.55 0.54 0.60 0.59
SCC 0.78 0.65 0.57 0.55 0.57 0.44
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as high-risk or low-risk as described in Additional file 1:
Supplementary Methods. The performances of these
two kinds of SVM classifiers are listed in Table 3. The
comparing results indicate the superiority of DPBM
even through it adopts a simple classification strategy.
As far as we know, there is only one published work to
construct a model for predicting bone metastases risks
of cancer patients [3], by using SCC (shrunken centroids
classifier) [52] method. Therefore, we also compared
DPBM with SCC. Since the data set used in the original
work is too small, we constructed SCC and evaluated its
performances on our data sets (the training samples
were labelled as high-risk or low-risk as described in
Additional file 1: Supplementary Methods, and 35 dys-
regulated genes were used as features). The results are
also listed in Table 3, from which we can see that our
DPBM performs better than SCC that has been used in
previous work [3].
Discussion and conclusions
Predicting the bone metastases risks for breast cancer
patients is essential in cancer therapy, which is an urgent
challenge now [5]. In this work, we have proposed a
Dysregulated Pathway Based prediction Model (DPBM)
to address this problem. We first selected the candidate
genes (correlated with the bone metastasis) by bootstrap-
ping strategy. Then we identified the dysregulated path-
ways enriched by the candidate genes. After that, we used
the dysregulated genes in each dysregulated pathway to
construct a sub-model to predict the bone metastasis risk
separately. Finally, we combined all sub-models together
by using majority voting strategy as an ensemble model,
DPBM, to predict the risk of bone metastasis. Validation
results on test set and independent set have shown the
great prediction power of DPBM.
By literature investigation, most of the dysregulated
pathways and dysregulated genes are related to bone me-
tastasis. In addition, the dysregulated genes tend to have
higher degrees and betweenness centralities in PPI net-
work, suggesting that they play critical roles in the bio-
logical functions. By comparing the functional groups to
which the dysregulated genes of bone and non-bone me-
tastases belong, we found that the immune system may be
essential in the bone specific metastasis of breast cancer.All the results illustrate that the dysregulated genes
may be good biomarker candidates. The facts that
DPBM consistently performs well in both test set and
independent set may be due to the following merits:
(1) we used the pathways to filter the candidate genes,
which can help to remove those genes less essential to
the bone metastasis; (2) instead of selecting pathways or
other functional gene sets via the activity differences be-
tween different phenotypes, we selected the dysregulated
pathways enriched by the discriminative genes, which
can help to preserve the useful information for classifica-
tion and reduce noises; (3) we constructed one sub-
model based on each dysregulated pathway, and then
combined all sub-models by majority voting strategy.
The ensemble classifier usually performs better than
simple classifiers [53].
In this work, although we have collected 855 samples,
the samples with the metastases to other specific organs
are still insufficient, that is why we merged all samples
with metastatic tumour of the other organs as one group
(non-bone metastases group). This is reasonable for us
to understand the difference between the bone metasta-
sis and other organ metastases. Of course, if the samples
with other organ metastases are sufficient, the differ-
ences among different metastases organs may also be
well studied.Additional files
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